Naringenin and hesperetin of the GliceFen® formulation target the insulin resistance mechanisms of T2DM [4], while the combination of curcumin, polydatin, and quercetin, which is present in both the GliceFen® and BlastiMin Complex® nutraceuticals, possesses antioxidant and anti-inflammatory properties, exerted through the reduction of ROS, IL-1β and IL-8 levels [3]. The gene discussed is CXCL8; the disease is type 2 diabetes mellitus.